Search Results - "Kopp, William C."

IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood by Sneller, Michael C., Kopp, William C., Engelke, Kory J., Yovandich, Jason L., Creekmore, Stephen P., Waldmann, Thomas A., Lane, H. Clifford

“…IL-15 promotes activation and maintenance of natural killer (NK) and CD8+ T effector memory (TEM) cells, making it a potential immunotherapeutic agent for the…”
Get full text

Whole Blood Cryopreservation in Epidemiological Studies by HAYES, Richard B, SMITH, Craig O, HUANG, Wen-Yi, READ, Yvonne, KOPP, William C

“…Standardized and cost-effective biological sample collection, processing, and storage procedures are needed in large-scale epidemiological studies to provide…”
Get full text

Peripheral blood immunologic phenotype of population-based breast cancer cases and matched controls by Goedert, James J., Pfeiffer, Ruth, Zhu, Mingzhu, Yang, Xiaohong R., Garcia-Closas, Montserrat, Lissowska, Jolanta, Kopp, William C.

“…Eur J Clin Invest 2012; 42 (5): 572–574…”
Get full text

Lymphocyte subsets in hemophilic patients with hepatitis C virus infection with or without human immunodeficiency virus co-infection: a nested cross-sectional study by Zhang, Mingdong, O'brien, Thomas R, Kopp, William C, Goedert, James J

“…BACKGROUND: With chronic infection, hepatitis C virus (HCV) RNA can be detected in B cells and associated with B-cell disorders, but these are not well…”
Get full text

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer : clinical and immunological effects by EWEL, C. H, URBA, W. J, BEVERIDGE, J. M, MCNITT, K. L, CREEKMORE, S. P, KOPP, W. C, SMITH, J. W, STEIS, R. G, ROSSIO, J. L, LONGO, D. L, JONES, M. J, ALVORD, W. G, PINSKY, C. M

“…We have performed a phase IB study of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose (poly-ICLC) in combination with…”
Get full text

Immune reactivity after adenoviral‐mediated aquaporin‐1 cDNA transfer to human parotid glands by Alevizos, I, Zheng, C, Cotrim, AP, Goldsmith, CM, McCullagh, L, Berkowitz, T, Strobl, SL, Malyguine, A, Kopp, WC, Chiorini, JA, Nikolov, NP, Neely, M, Illei, GG, Baum, BJ

“…Objectives The purpose of this study was to examine the humoral and cellular immune reactivity to adenoviral vector (AdhAQP1) administration in the human…”
Get full text

Interleukin 1α Increases Serum Leptin Concentrations in Humans by Janik, John E, Curti, Brendan D, Considine, Robert V, Rager, Helen C, Powers, Geraldine C, Alvord, W. Gregory, Smith, John W, Gause, Barry L, Kopp, William C

“…Leptin, the protein product of the ob gene, regulates appetite and body weight in animals. Endotoxin and cytokines, induced by endotoxin, interleukin (IL) 1…”
Get full text

A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2 by Holmund, J T, Kopp, W C, Wiltrout, R H, Longo, D L, Urba, W J, Janik, J E, Sznol, M, Conlon, K C, Fenton, R G, Hornung, R

Get more information

Continuous Infusion of the Anti-CD22 Immunotoxin IgG-RFB4-SMPT-dgA in Patients With B-Cell Lymphoma: A Phase I Study by Sausville, Edward A., Headlee, Donna, Stetler-Stevenson, Maryalice, Jaffe, Elaine S., Solomon, Diane, Figg, William D., Herdt, Jean, Kopp, William C., Rager, Helen, Steinberg, Seth M., Ghetie, Victor, Schindler, John, Uhr, Jonathan, Wittes, Robert E., Vitetta, Ellen S.

“…lgG-RFB4-SMPT-dgA consists of deglycosylated ricin A chain (dgA) coupled to the monoclonal antihuman CD22 antibody, RFB4. This study determined the maximally…”
Get full text

Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells by Hestdal, K, Ruscetti, FW, Ihle, JN, Jacobsen, SE, Dubois, CM, Kopp, WC, Longo, DL, Keller, JR

“…Murine bone marrow cells expressing the cell surface Ag RB6-8C5 were identified by fluorescence-activated cell-sorting analysis using a rat IgG mAb. The…”
Get full text

Cycling of human dendritic cell effector phenotypes in response to TNF‐α: modification of the current ‘maturation’ paradigm and implications for in vivo immunoregulation by Nelson, Edward L., Strobl, Susan, Subleski, Jeff, Prieto, Darue, Kopp, William C., Nelson, Peter J.

“…ABSTRACTDendritic cells (DCs) are potent antigen presenting cells reported to undergo irreversible functional ‘maturation’ in response to inflammatory signals…”
Get full text

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer by Curti, B D, Ochoa, A C, Powers, G C, Kopp, W C, Alvord, W G, Janik, J E, Gause, B L, Dunn, B, Kopreski, M S, Fenton, R, Zea, A, Dansky-Ullmann, C, Strobl, S, Harvey, L, Nelson, E, Sznol, M, Longo, D L

“…We performed a phase I trial to determine whether in vivo expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to…”
Get more information

Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells by Loeffler, CM, Smyth, MJ, Longo, DL, Kopp, WC, Harvey, LK, Tribble, HR, Tase, JE, Urba, WJ, Leonard, AS, Young, HA

“…The causes of the decreased immune responsiveness in tumor-bearing hosts are incompletely understood. The impact of a decreased immune response in cancer…”
Get full text

CORRELATION OF HUMAN CD56+CELL CYTOTOXICITY AND IFN-γ PRODUCTION by Derby, Eric G., Reddy, Vasavi, Nelson, Edward L., Kopp, William C., Baseler, Michael W., Dawson, Jeffrey R., Malyguine, Anatoli M.

“…The use of an IFN-γ ELISPOT assay to evaluate cellular immune responses has gained increasing popularity, especially as a surrogate measure for cytotoxic T…”
Get full text

Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin by Miller, Langdon L., Korn, Edward L., Stevens, Diane S., Janik, John E., Gause, Barry L., Kopp, William C., Holmlund, Jon T., Curti, Brendan D., Sznol, Mario, Smith, John W., Urba, Walter J., Donegan, Sarah E., Watson, Thelma M., Longo, Dan L.

“…This dose-escalation study was performed to evaluate the hematologic activity, biological effects, immunogenicity, and toxicity of PIXY321 (an…”
Get full text

Treatment with Tumor Necrosis Factor-α and Granulocyte–Macrophage Colony-Stimulating Factor Increases Epidermal Langerhans' Cell Numbers in Cancer Patients by Janik, John E., Miller, Langdon L., Kopp, William C., Taub, Dennis D., Dawson, Harry, Stevens, Diane, Kostboth, Paige, Curti, Brendan D., Conlon, Kevin C., Dunn, Barbara K., Donegan, Sarah E., Ullrich, Robert, Alvord, W.Gregory, Gause, Barry L., Longo, Dan L.

“…Dendritic cells (DCs) initiate primary and stimulate secondary T-cell responses. We conducted a phase I trial of tumor necrosis factor (TNF-α) and…”
Get full text

Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin by Yoe, Joe, Gause, Barry L., Curti, Brendan D., Longo, Dan L., Bagg, Adam, Kopp, William C., Janik, John E.

“…The association of T‐cell large granular lymphocyte (LGL) leukemia and rheumatoid arthritis is well described and it is now recognized that these patients and…”
Get full text

Deoxycoformycin-Induced Immunosuppression in Patients With Hairy Cell Leukemia by Urba, Walter J., Baseler, Michael W., Kopp, William C., Steis, Ronald G., Clark, Jeffrey W., Smith II, John W., Coggin, David L., Longo, Dan L.

“…Immune function in patients with hairy cell leukemia (HCL) was examined serially during treatment with alternating monthly cycles of recombinant interferon…”
Get full text

Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer by W C Kopp, W J Urba, H C Rager, W G Alvord, J J Oppenheim, J W Smith, 2nd, D L Longo

“…The interleukin 1 receptor antagonist (IL-1ra) is a naturally occurring molecule that shares homology with IL-1alpha and IL-1beta and binds competitively to…”
Get full text

Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma by Janik, John E., Miller, Langdon L., Longo, Dan L., Powers, Geraldine C., Urba, Walter J., Kopp, William C., Gause, Barry L., Curti, Brendan D., Fenton, Robert G., Oppenheim, Joost J., Conlon, Kevin C., Holmlund, Jon T., Sznol, Mario, Sharfman, William H., Steis, Ronald G., Creekmore, Stephen P., Alvord, W. Gregory, Beauchamp, Ann E., Smith, John W.

“…Background: The rising incidence of malignant melanoma and the lack of curative therapies for metastatic disease represent a therapeutic challenge. New agents…”
Get full text